Michael joined SV Health Investors as a Venture Partner in 2014.
Michael is a physician-scientist, research leader and executive with broad experience in healthcare. He brings with him extensive experience as an industry and academic leader in research and development with a focus on molecular and cellular cardiovascular biology. From 2010 through 2013, he served as Senior Vice President and head of cardiovascular research for Merck Research Laboratories. In that role he had global responsibility for, and scientific direction of, cardiovascular research from drug discovery through late development.
Prior to Merck, Michael served as founder, Executive Director and the first Chief Scientific Officer of the Molecular Cardiology Research Institute at Tufts Medical Center and Tufts University School of Medicine. He previously spent five years on the cardiovascular faculty of the Brigham and Women’s Hospital and Harvard Medical School.
Michael did an internal medicine internship and residency, followed by a fellowship in cardiovascular medicine, all at Brigham and Women’s Hospital and Harvard Medical School. As a physician-scientist, he studied signal transduction pathways regulating vascular and cardiac function and published over 150 papers.
BA, Amherst College; MD, Harvard Medical School.
Outside of SV
Michael serves as the Executive Chairman of Cardurion Pharmaceuticals and as a Director of Foghorn Therapeutics.